

Galsat Therapeutics

Breathing new life into respiratory disease therapy

WHAT WE DO

Galsat delivers an advanced and much simpler Asthma treatment using an oral delivery of Fidarestat, an aldose reductase inhibitor. The oral delivery capability of Fidarestat yields a higher medication compliance rate and delivery efficiency than traditional inhalers.

400 M Asthma sufferers WW

25 M Asthma sufferers US

7 M Children suffer in the US



MARKET SIZE

Each year, the cost of treating Asthma in the United States is approximately 10% of all medications costs combined.

COMPETITORS



PROGRESS & MILESTONES

- Developed and tested novel therapeutic drug to treat inflammatory disorders like Asthma
- Successfully tested in animal models; human clinical samples tested show high effectiveness in treating Asthma
- Phase II/III clinical trial studies in the US and Japan yielded no irreversible adverse events in patients

TARGET CUSTOMER PAIN POINTS

- Patients, especially children, with cumbersome and minimally effective Asthma regimens including inhalers
- Hospitals and clinics should see fewer incidents of non-compliance and associated side effects
- Health Departments will see decreases in cost of care as a result of easier treatment and greater adherence to provider recommendations

THE PRODUCT

- [PROTOTYPE] Fidarestat tablets
- [PROTOTYPE] Fidarestat syrup

DIFFERENTIATION

- Convenience of taking pills and syrups as opposed to inhalers
- Safer administration with less risk of patients misusing (under- or over-dosing) on Asthma medication
- Lower cost will encourage compliance for patients with the lifetime disease burden

MANAGEMENT TEAM

Satish Srivastava, PhD ♦ William Calhoun, MD ♦ Seprel Erzurum, PhD ♦ Alexander Vo, PhD